Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Af­ter brief stops in Paris and Boston, John Car­roll and the End­points crew are stay­ing on the road in Oc­to­ber with their re­turn for a live/stream­ing EU­BIO22 in Lon­don. The hy­brid event fire­side chats and pan­els on mR­NA, on­col­o­gy and the crazy pub­lic mar­ket. We hope you can join him there.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER